Company Profile: Gambro
Background
Gambro was a global medical technology company specializing in dialysis products and therapies for kidney and liver care. Founded in 1964 in Lund, Sweden, by Holger Crafoord, the company developed the first single-use artificial kidney, revolutionizing renal care. By 2013, Gambro employed approximately 8,000 people, with production facilities in nine countries and sales in over 100 countries.
Key Strategic Focus
Gambro's strategic focus encompassed the development, manufacturing, and supply of products and therapies for chronic and acute kidney and liver dialysis, as well as other extracorporeal therapies. The company aimed to improve patient outcomes through innovative renal and hepatic care technologies, serving hospitals, dialysis clinics, and healthcare providers worldwide.
Financials and Funding
In 2006, Gambro was acquired by Indap AB, a joint venture between Swedish investment companies EQT and Investor AB. The company was subsequently split into three independent entities: Gambro Renal Products, Caridian BCT, and Gambro Healthcare. In 2013, Gambro was acquired by Baxter International Inc. for an enterprise value of SEK 26.5 billion (approximately $4 billion).
Pipeline Development
Gambro's product pipeline included a range of dialysis machines, dialyzers, bloodlines, and solutions for both chronic and acute renal care. Notable products included the AK 96™ system for in-center hemodialysis and the Prismaflex® system for acute care. The company also developed the Polyflux filter-based dialysis system, enhancing dialysis efficiency.
Technological Platform and Innovation
Gambro was recognized for its pioneering innovations in dialysis technology, such as the first single-use artificial kidney and the first computer-controlled dialysis machine. The company's technological platforms included advanced monitors, dialyzers, bloodlines, cyclers, and dialysis solutions, contributing to improved treatment quality and efficiency in dialysis care.
Leadership Team
Specific details about Gambro's leadership team are not readily available.
Competitor Profile
Market Insights and Dynamics
The global dialysis market has experienced significant growth due to the increasing prevalence of chronic kidney disease. Major players in the market include Fresenius Medical Care, Baxter International (post-acquisition of Gambro), and B. Braun Melsungen AG. These companies compete in various segments, including hemodialysis machines, dialyzers, and peritoneal dialysis products.
Competitor Analysis
- Fresenius Medical Care: A leading provider of dialysis products and services, Fresenius holds a significant market share in dialyzers and dialysis machines.
- Baxter International: After acquiring Gambro, Baxter expanded its presence in the dialysis market, offering a comprehensive range of renal care products and therapies.
- B. Braun Melsungen AG: A major player in the dialysis field, B. Braun offers a spectrum of dialysis machines and supplies, competing with Fresenius and Baxter in various product categories.
Strategic Collaborations and Partnerships
Gambro's strategic collaborations included partnerships with healthcare providers and other medical technology companies to enhance its product offerings and expand its market reach. Specific details about these collaborations are not readily available.
Operational Insights
Gambro's operational strategy focused on innovation and efficiency in dialysis care. The company invested in research and development to deliver cutting-edge solutions to dialysis clinics and intensive care units, aiming to improve treatment quality and operational efficiency.
Strategic Opportunities and Future Directions
Post-acquisition by Baxter, the combined entity aimed to leverage Gambro's innovations and Baxter's global presence to strengthen its position in the renal care market. The strategic direction focused on expanding product portfolios, enhancing research and development capabilities, and improving patient outcomes through advanced renal and hepatic care technologies.
Contact Information
As of the latest available information, Gambro's official website existed prior to the acquisition, but since 2013, Gambro's operations have been integrated into Baxter's renal care division.
